Cargando…

Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies

Detalles Bibliográficos
Autores principales: Monti, Sara, Balduzzi, Silvia, Delvino, Paolo, Bellis, Elisa, Quadrelli, Verdiana Serena, Montecucco, Carlomaurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211079/
https://www.ncbi.nlm.nih.gov/pubmed/32241793
http://dx.doi.org/10.1136/annrheumdis-2020-217424
_version_ 1783531388985671680
author Monti, Sara
Balduzzi, Silvia
Delvino, Paolo
Bellis, Elisa
Quadrelli, Verdiana Serena
Montecucco, Carlomaurizio
author_facet Monti, Sara
Balduzzi, Silvia
Delvino, Paolo
Bellis, Elisa
Quadrelli, Verdiana Serena
Montecucco, Carlomaurizio
author_sort Monti, Sara
collection PubMed
description
format Online
Article
Text
id pubmed-7211079
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-72110792020-05-12 Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Monti, Sara Balduzzi, Silvia Delvino, Paolo Bellis, Elisa Quadrelli, Verdiana Serena Montecucco, Carlomaurizio Ann Rheum Dis Letter BMJ Publishing Group 2020-05 2020-04-02 /pmc/articles/PMC7211079/ /pubmed/32241793 http://dx.doi.org/10.1136/annrheumdis-2020-217424 Text en © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
spellingShingle Letter
Monti, Sara
Balduzzi, Silvia
Delvino, Paolo
Bellis, Elisa
Quadrelli, Verdiana Serena
Montecucco, Carlomaurizio
Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
title Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
title_full Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
title_fullStr Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
title_full_unstemmed Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
title_short Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
title_sort clinical course of covid-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies
topic Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211079/
https://www.ncbi.nlm.nih.gov/pubmed/32241793
http://dx.doi.org/10.1136/annrheumdis-2020-217424
work_keys_str_mv AT montisara clinicalcourseofcovid19inaseriesofpatientswithchronicarthritistreatedwithimmunosuppressivetargetedtherapies
AT balduzzisilvia clinicalcourseofcovid19inaseriesofpatientswithchronicarthritistreatedwithimmunosuppressivetargetedtherapies
AT delvinopaolo clinicalcourseofcovid19inaseriesofpatientswithchronicarthritistreatedwithimmunosuppressivetargetedtherapies
AT belliselisa clinicalcourseofcovid19inaseriesofpatientswithchronicarthritistreatedwithimmunosuppressivetargetedtherapies
AT quadrelliverdianaserena clinicalcourseofcovid19inaseriesofpatientswithchronicarthritistreatedwithimmunosuppressivetargetedtherapies
AT montecuccocarlomaurizio clinicalcourseofcovid19inaseriesofpatientswithchronicarthritistreatedwithimmunosuppressivetargetedtherapies